Aerie Pharma (AERI): Reiterating Buy Ahead Of 2 Major Catalysts - Needham

August 23, 2016 7:02 AM EDT
Get Alerts AERI Hot Sheet
Price: $33.28 --0%

Rating Summary:
    9 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 22 | Down: 34 | New: 15
Trade AERI Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Needham & Company analyst, Serge Belanger, reiterated his Buy rating on Aerie Pharma (NASDAQ: AERI) ahead of two major catalysts expected in 3Q16:
1) the NDA filing for Rhopressa
2) the top-line readout of MERCURY-1, the first of two pivotal ph 3 studies evaluating Roclatan as a glaucoma treatment.

The analyst stated "The positive ph 2b results of Roclatan and the completed Rhopressa clinical program give us confidence for Roclatan's ph 3 MERCURY program, and extending positive 29-day ph 2b efficacy/safety results out to 12 wks (primary endpoint) and beyond. Roclatan has demonstrated the potential to play a major role in treating glaucoma, thus we view upcoming results as a major valuation catalyst for AERI".

No change to the price target of $45.

For an analyst ratings summary and ratings history on Aerie Pharma click here. For more ratings news on Aerie Pharma click here.

Shares of Aerie Pharma closed at $19.46 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Needham & Company

Add Your Comment